To test the effect of pharmaceutical case management (PCM) on medication safety and health care utilization.
M edication safety has become a major concern in the United States. 1 The rate of adverse drug events increases substantially as the number of drugs in a regimen increases. 2, 3 Published evidence strongly suggests that pharmacist-physician teams can increase medication safety. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Recently, Gurwitz et al. 19 concluded from their prospective cohort study of more than 30,000 Medicare enrollees that adverse drug events are common and preventable in the community. They specifically recommend that "further development and testing of new approaches to enhance collaborations between those who prescribe drugs and those who know the most about the specific drugs, that is, clinical pharmacists, should be pursued in the ambulatory setting." Numerous examples of innovative practice models in community pharmacy have emerged during the past 35 years. 4 Studies in community pharmacies have demonstrated that interventions and management by pharmacists can improve control of several chronic conditions, provide preventive services, and provide interventions that can significantly reduce the cost of therapy. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Several demonstration projects and research studies in community pharmacy have been conducted in Iowa. 12, 13, 20, 21 The Iowa Center for Pharmaceutical Care program has trained more than 200 practicing pharmacists in strategies to identify and resolve drug-related problems. 12, 13, 20, 21 The Iowa Medicaid Pharmaceutical Case Management (PCM) program is the first such program in the United States that formally recognizes pharmacists as providers and pays physician-pharmacist teams who deliver medication management services for high-risk patients in the community setting.
The Iowa Medicaid PCM program began with funds appropriated during the 2000 Iowa legislative session. The program was implemented as a state plan amendment and is an ongoing service for eligible patients receiving Medicaid. The program was designed to benefit a subset of individuals who are at very high risk for having adverse effects from their medications.
The design, fee structure, pharmacist qualifications, advisory board, and services provided during the first 3 months of patient enrollment have been previously published 22 and are reviewed only briefly here. The unique features of the PCM program are that both physicians and pharmacists are paid for their services and that a collaboratively determined action plan can be implemented by the pharmacist without requiring a patient visit to a physician. Under this initiative, both pharmacists and physicians provide and may be paid for one initial assessment ($75 each), up to four problem follow-up assessments ($40 each) per 12 months; up to two new problem assessments ($40 each) per 12 months; and up to one preventive follow-up assessment ($25 each) every 6 months. Eligible patients (noninstitutionalized Medicaid beneficiaries of any age who are taking at least 4 medications and with one of 12 specified diseases) receive an initial assessment by the pharmacist who makes recommendations to the physician in writing. Recommendations that are accepted or modified by the physician are considered an action plan. Pharmacists make problem followup assessments until all problems are resolved, communicating with the physician in each case. Once problems are resolved, preventive follow-up assessments can occur every 6 months, and new problems that arise episodically can trigger a new problem assessment and a new action plan.
The aim of the Iowa Medicaid PCM program is to avoid adverse drug events and the health system costs associated with these adverse effects. The means to accomplish this is by using more optimal, lower-risk medication regimens. The legislation that implemented the Iowa Medicaid PCM program also required program evaluation, and the results of that research are reported in this article.
Objectives
The primary objectives of this evaluation were to describe the extent and content of PCM services and determine the effect of the PCM program on medication safety. A secondary objective was to estimate the effect of PCM services on health care utilization.
AT A GLANCE

Synopsis:
The state-mandated evaluation of the initial experiences of pharmacists, physicians, and patients in the Iowa Medicaid Pharmaceutical Case Management (PCM) program is presented in this article. To improve medication effectiveness and safety, the PCM program reimburses pharmacists and physicians for interventions, monitoring, and follow-up in eligible Medicaid recipients. Medication appropriateness increased significantly among the PCM recipients, compared with eligible recipients who did not receive these interventions, and use of high-risk medications decreased significantly. Patients of pharmacies that adopted the program most intensely had a significant decrease in high-risk medication use. No differences in health care utilization or charges were found between PCM-eligible patients who received services and those who did not, even with charges for PCM services included.
Analysis 
Methods
Study Population
The design for the evaluation of the PCM program has been previously described. 22 A prospective cohort design was used and included patients who became eligible for PCM from October 1, 2000, through July 1, 2001, with follow-up through July 1, 2002. Thus the evaluation reports mainly on the PCM program start-up phase. The program was implemented with 117 participating pharmacies on October 1, 2000. Eligible patients were identified quarterly using pharmacy claims data from participating pharmacies. Noninstitutionalized Iowa Medicaid patients taking four or more long-term medications, including at least one medication representing 1 of specified 12 diseases (n = 3,037), were eligible (the 12 diseases were congestive heart disease, ischemic heart disease, diabetes mellitus, hypertension, hyperlipidemia, asthma, depression, atrial fibrillation, osteoarthritis, gastroesophageal reflux, peptic ulcer disease, and chronic obstructive pulmonary disease).To have complete claims data, we excluded from analysis all patients who were not continuously eligible for Medicaid from 6 months before through 12 months after the date on which they became eligible for PCM.
Data Sources and Variable Definitions
Data sources included Medicaid claims files, mailed questionnaires to eligible patients at baseline (mailed before the first day of eligibility for receipt of PCM services), quarterly fax surveys of all participating pharmacies, and review of problem-oriented patient records kept in pharmacies for recipients of the service. Variables constructed from these sources are described in the following sections.
Measures from Medicaid Claims Files
Receipt of PCM services was measured as at least one claim for PCM reimbursement filed within 9 months of the patient's PCM eligibility. Medication safety measures were constructed based on an "active drug list" constructed from pharmacy claims. A computer algorithm was developed to construct, from Medicaid pharmacy claims, a list of drugs considered "active" on the date a patient became eligible for PCM (the "index" date). 23 This same process was conducted 9 months later (i.e., on the "follow-up" date).
Two measures of medication safety were applied to these drug lists. The first measure was a rating of medication problems for all patients who received PCM services, which was constructed from a clinical pharmacist-conducted structured review of patients' pharmacy records (see Measures From Patients' Pharmacy Records below). The second measure was use of medications considered to be inappropriate for use among persons aged 65 and older (hereafter referred to as "high-risk" medication use). 24 This measure was constructed for all PCM-eligible elders (aged 65 and over), inclusive of those who did and did not receive the services.
Measures of health care utilization included number of claims and charges to Medicaid for pharmacy, institutional, and medical services. The PCM claims from both pharmacies and physicians were included in the "medical" claims analysis (because they were submitted on a Health Care Financing Administration [HCFA-1500] claim form, they reside in the medical claims file).
Measures from Mailed Baseline Patient Questionnaires
Prevalence of adverse drug reactions was assessed in the patient questionnaires using the question, "In the past year, have you noticed any side effects, unwanted reactions, or other problems from medications you were taking?" 2 Generic health status was measured on the questionnaire with the Medical Outcomes Study Short Form (SF-36), using the physical and mental health summary scores. 25 
Measures from Quarterly Pharmacy Fax Survey
Three months after receiving their list of eligible patients, pharmacies received fax surveys querying the status of eligible patients, and these were returned for 96.7% of eligible patients. These data were used to measure the intensity with which a pharmacy provided PCM. 22 The percentage of PCM-eligible patients for whom a pharmacist recommendation was completed was calculated each quarter for each pharmacy as a measure of the intensity of PCM adoption. A pharmacy that completed recommendations for at least 50% of patients in at least one quarter was considered a high-intensity pharmacy. Moderate-intensity pharmacies were those that completed recommendations for at most 25% to 49% of patients in any quarter, low-intensity pharmacies completed recommendations for 1% to 24% of patients, and zero-intensity pharmacies completed no recommendations during the study period.
Measures from Patients' Pharmacy Records
Pharmacists who provide PCM are required to maintain documentation of all PCM services in problem-oriented notes in the SOAP format (subjective, objective, assessment, plan). Copies of these records were obtained for those who received PCM services 1 year after each patient's initial PCM eligibility date. These records served as the source of detailed information about medical diagnoses, medication purpose, and dosage, which were required for construction of a complete Medication Appropriateness Index (MAI) score for patients who received PCM services. MAI scores are derived by rating each medication using 10 weighted explicit criteria that are classified by the reviewer as either "appropriate," "marginally appropriate," or "inappropriate," on the basis of strict operational definitions for each criterion. 26, 27 The 10 criteria that contribute to the MAI score are: indication, effectiveness, correct dosage, correct directions, practical directions, drug-drug interaction, drug-disease interaction, duplication, duration of treatment, and cost. The MAI score for a medication can range from 0 to 18 (higher is more inappropriate). Patient-specific scores depend on the number of medications rated so both the summed MAI score and the mean MAI score (i.e., the average MAI rating for all medications prescribed) were examined. 27 The MAI was scored using the weights supplied by the developer; items coded as inappropriate ("C" rating) were assigned weights. 26 The MAI was calculated from problem-oriented patient records kept by pharmacists, which has previously been demonstrated to be reliable in community pharmacy settings. 28 MAI scores were determined by a clinical pharmacist blinded to PCM intensity and pharmacy. The change in full MAI score from the index date (before PCM) to the 9-month follow-up date was evaluated for all patients who received the service. In addition to the MAI reviews, a 40% random sample of these records was abstracted to describe the action plans developed by the care teams.
Statistical Methods
To determine the effects of the PCM program, three types of comparisons were made: 1. Among patients who received PCM services, medication safety on the index date was compared with safety of medications on the 9-month follow-up date (i.e., using a single group pre-post design). 2. Between PCM-eligible patients who received PCM services and PCM-eligible patients who did not receive PCM services, the change over time in use of high-risk medications, number of active drugs, cost of their medications, and medical and institutional utilization (i.e., a comparison group design). 3. Among PCM-eligible patients, regardless of receipt of services, the effect of pharmacy intensity on change in use of high-risk medications and on change in health care utilization.
The relationships of continuous variables at baseline were assessed using t-tests, analysis of variance (ANOVA), analysis of covariance (ANCOVA) (controlling for age and gender), and nonparametric procedures. Correlation analyses used Pearson or Spearman methods. Comparisons between categorical variables were assessed using chi-square statistics or exact nonparametric methods for small sample sizes. Cochran-Mantel-Haenszel methods were used when controlling for age, gender, and other characteristics. The relationship of continuous and categorical variables was assessed with Wilcoxon/Kruskall-Wallis methods, ANOVA, and ANCOVA (controlling for age and gender).
Longitudinal statistical analysis of change over time in medication safety and health care utilization used the generalized estimating equations (GEE) approach. 29 This method accounts for correlations between repeated measures. GEE supports generalized linear models for a variety of longitudinal or correlated data and can be used for Poisson, logistic, gamma, and normal distribution analyses. The logistic function was used for binomial outcomes, the cumulative logistic function for multinomial outcomes, and the normal distribution for continuous outcomes. Binomial variables included individual categories of medication safety problems such as the 10 domains for the MAI score and use/nonuse of high-risk medications. Multinomial outcomes included number of emergency department claims per month and number of inpatient claims per month. Continuous outcomes included number of drugs, total MAI scores, number of outpatient claims per month, number of medical service claims per month, and log charges. Models with dollar amounts used log dollars. Repeated measures analyses for repeated observations over time used the patient identification number as the unit of repetition.
Results
Description of Eligible Patients
A total of 3,037 patients were eligible for PCM services during the study enrollment year ( Table 1 ). The mean (± SD) age was 52.5 ± 20.2 years. Almost two thirds of eligible patients were aged 45 or older, 28.3% were aged 65 and older, and 6.4% were children. Adults ranged from 18 years to 101 years of age. Overall, 71.4% of patients were women. For patients who became eligible for PCM services during the four calendar quarters of the study-beginning Table 1 ) and 1,599 services. Of the 1,599 PCM services reimbursed, 90% (n = 1,440) were submitted on claims from pharmacists and 159 were from physicians. Among the 3,037 patients who were eligible for PCM, 2,211 (72.8%) remained continuously eligible for Medicaid from 6 months before through 12 months after the date at which they became eligible for PCM services and constituted the analysis dataset (Table 1 ). Of these, 524 patients received PCM services. A total of 659 patients-including 180 who received PCM and 479 who did not-responded to the baseline questionnaire (Table 1) .
Of 117 eligible pharmacies statewide, 114 had eligible patients assigned in at least one quarter. Of these, 28 pharmacies were classified as high intensity, 46 as moderate intensity, 21 as low intensity, and 19 as zero intensity. Table 2 displays the baseline (before Received PCM 524
Responded to questionnaire 180
Pharmacy record available 507
Did not receive PCM 1,687
Responded to questionnaire 479
Pharmacy record available 0
Abbreviation used: PCM, pharmaceutical case management.
a Remained continuously eligible for Medicaid from 6 months before through 12 months after the date at which they became eligible for PCM services.
PCM) sociodemographic, health status, and medication characteristics of those who received PCM services compared with those who were eligible for but did not receive PCM services, adjusted for between-group differences in patient age and gender. After adjusting for age differences, those who received PCM still took a higher number of medications and were more likely to be women and to have drug-drug interactions. The types of drugs taken by those who did and did not receive PCM services were similar. Regardless of whether they received PCM services, more than one half of PCM-eligible patients had at least one indicator of inappropriate medication use during the baseline (pre-PCM) period. After adjusting for age and gender, at baseline those who received PCM services were similar to those who did not in overall, physical, and mental health, prior use of urgent care services, and prevalence of adverse drug reactions. Their health status, as measured using the 36-item short-form health survey (SF-36), was markedly lower than the national average for physical health ( in the year before PCM services, a rate 2.6 times that observed using the same question in a survey of a population-based sample of elderly Iowans. 2 Categorizing Pharmacists' Recommendations A random sample of 203 patient pharmacy charts was reviewed to characterize the nature of the problems identified, recommendations made by pharmacists, and physician acceptance of these recommendations. The communication form between the pharmacist and the physician was the source used to identify recommendations.
Pharmacists identified a mean (± SD) of 2.6 ± 1.6 (median 2.0, range 1-9) medication problems per patient and made 3.8 ± 3.0 (median 3.0, range 1-15) recommendations per patient. The most common types of problem detected were: therapeutic monitoring needed (41.9% of patients, 16.7% of recommendations); untreated conditions (40.4% of patients, 17.6% of recommendations); and undertreated conditions (37.0% of patients, 14.3% of recommendations). The most common type of recommendation made was to start a new medication (Table 3; 51.7% of patients, 24.5% of all recommendations). Other common recommendations were to change the dose of a medication, change a medication to an alternate therapy, monitor the medicine or disease (e.g., monitor drug levels or blood pressure), or to discontinue a medication.
Physicians accepted a mean (± SD) of 1.9 ± 2.0 (median 2.0, range 0-15) recommendations per patient. Of 771 recommendations made by pharmacists, 379 (49.2%) were accepted by physicians. Physicians required a mean of 8.9 days (median, 4.0 days) to relay their decision about pharmacists' recommendations.
Effect of PCM on Medication Safety
Change Over Time Among Those Who Received PCM Services A pharmacy record was available for 507 of 524 patients who had received PCM (Table 1) . Pharmacy records, and hence MAI scores, were not available for those who did not receive the service. Changes in MAI scores, number of medications, and individual medication problems between the index date (the date a patient became eligible for PCM services) and the follow-up date (9 months later) were analyzed using GEE for repeated measures. We used normal regression methods when the dependent variable was a total score and logistic methods when the dependent variable was binary (yes/no). Independent variables were age (continuous), gender, pharmacy intensity, a time indicator (1 if index date; 2 if follow-up date), and a time by pharmacy intensity interaction term. Table 4 displays the medication problems and MAI scores at the index date and the follow-up date. Overall, nearly one half (46.1%) of medications and 92.1% of patients had at least one medication problem on the index date (pre-PCM). By closeout, the percentage of medications with problems decreased in 8 of 10 MAI domains for those who received PCM. Overall, the percentage of medications with any problems decreased from 46.1% to 40.9% (P < .001). No significant time by intensity interactions were identified. This indicates that the change in MAI measures for patients who received PCM did not vary by PCM intensity of the pharmacy.
The mean number of ingredients increased significantly from 7.9 to 8.2 among those who received PCM and the mean MAI score decreased significantly from 9.4 to 8.3, a 12% improvement (P < .001). After receiving PCM services, patients were significantly less likely to be taking a drug without a valid indication for use or that was considered ineffective or inappropriate for age (effectiveness), had an incorrect dosage, interacted with a patient disease, or had an inappropriate duration of use. Though not statistically significant, a trend was observed for patients to be less likely to be taking a drug that had incorrect directions or unjustifiable expense. These results indicate that medication use improved significantly from before to 9 months after patients received PCM services. This was despite an increase in mean number of active ingredients from baseline to follow-up (Table 4) .
Though the MAI evaluation provided a detailed assessment of change in the domains of medication appropriateness, the single group pre-post comparison is not a strong design for evaluating the impact of the intervention. A comparison group design was possible for one domain of medication safety and also for analysis of health care utilization effects.
Change in Use of High-Risk Medications
To compare change in medication problems for patients who received PCM services with those who were eligible but did not receive them, we used the list of medications established through a consensus-forming process by Beers 24 to be inappropriate for people aged 65 and over. Other pharmacy claims-based measures were tested and found to have poor validity (kappa coefficients of 0.28 or lower for agreement with clinician record-based review). Clinician review of patient records to identify use of inappropriate drugs (Beers' list) agreed well with the computerized review of pharmacy claims data (kappa = 0.76).
To test whether those who received PCM differed in rate of change from those who did not receive PCM, we used a GEE repeated-measures logistic model with medication safety (yes/no) as the dependent variable, controlled for age and gender, and included a time by PCM interaction in the model. The monthly repeated measure of use of high-risk drugs (yes/no) was calculated using the active drug list for the first of each month, from 3 months before through 9 months after the index date. Only patients aged 65 and older were included in the high-risk drug use analyses.
A significant time by intervention interaction (P = .032) indicated that, after adjusting for age and gender, PCM recipients had a significantly greater decrease in use of high-risk medications than did PCM-eligible patients who did not receive the service. Figure  1 shows that the decline in high-risk medication use (Beers' list) occurred after patients became eligible for PCM.
We also compared the change from index date to follow-up date in prevalence of high-risk drugs within the two study groups. This model used only one prevalue and one postvalue (index date and follow-up date, respectively) in a GEE repeated-measures logistic methods analysis, controlled for age and gender, and tested for a a The index date was the day first eligible for PCM: follow-up was 9 months after the index date.
b Because of incomplete information in some records, the number of medications rated was less than the total number of medications (n = 4,001 at index date and n = 4,141 at follow-up) and the number of patient charts rated was less than the total patient charts available (n = 507 at index date and n = 505 at follow-up).
c P value was for difference between index and follow-up dates based on generalized estimating equations for repeated measures with two time points for continuous ("normal") and binomial variables.
d Ingredients were the active components of drug products; some combination products contained multiple active ingredients.
e The MAI score was calculated by summing the weight for each MAI problem for each active ingredient. The mean MAI score per medication was the total of the summated MAI scores divided by the total number of active ingredients rated. The mean MAI score per patient was the total of the summated MAI scores (excluding patients with missing data for any MAI problem) divided by the number of patients (n = 471 index date, n = 469 follow-up).
time by PCM difference. Those who received PCM had a significant (P < .05) decrease in prevalence of high-risk medication use (from 43.4% to 32.6%). In contrast, no significant change occurred among those who were eligible for but did not receive PCM services (from 35.8% to 34.4%). Interestingly, patients who received PCM services had a higher baseline prevalence of using these drugs than did patients who did not receive PCM services, suggesting that pharmacists may have targeted patients at higher risk. To evaluate whether there was a dose-response relationship between the intensity with which the service was adopted by the pharmacy and the magnitude of improvement in medication safety, we examined the effect of pharmacy intensity on change in use of high-risk medications over time for all PCM-eligible patients. Because low-intensity pharmacies provided PCM to so few patients, the effect of PCM should not have been detectable in the patient population of these pharmacies (i.e., the intervention effect would have been diluted by the large number of patients who did not receive the intervention). In contrast, for high-intensity pharmacies where the majority of PCM-eligible patients actually received the service, the effect of PCM was expected to be detectable.
We therefore hypothesized that there would be a significant time by pharmacy intensity interaction, specifically that medication safety would improve in high-intensity pharmacies to a greater extent than it would in low-intensity pharmacies. To test this hypothesis we used a GEE repeated-measures logistic model with high-risk medication use (yes/no) as the dependent variable at two time points (index date and follow-up date), controlled for age and gender, and looked for a significant time by PCM intensity interaction. We also tested for a significant time effect within each of the four intensity groups.
As displayed in Figure 2 , this hypothesis was supported. A significant P value (P = .005) was found for the time by intensity interaction, indicating that patients of higher-intensity pharmacies had a greater decrease in high-risk medication use. In addition, the decrease over time among high-intensity pharmacies was significant (P < .001), whereas for other intensity groupings it was not. PCM-eligible patients receiving prescriptions at high-intensity pharmacies had a higher baseline prevalence of medication problems than did patients receiving prescriptions from lower-intensity pharmacies (P < .05).
Effect of PCM Services on Medication Use
Adjusted for age and gender differences, when compared with PCM-eligible patients who did not receive PCM, PCM services 
Percent
PCM
No PCM
The time by interaction P value is .032
Study Month (Pre-PCM months 1-3; PCM-eligible 5-13)
had no significant effect on the net number of medications or medication charges (Table 5) . For these models we used GEE repeated-measures "normal" regression methods with number of medications or charges as the dependent variable at two time points (index date and follow-up date). We controlled for age and gender and tested for a significant time by PCM interaction to evaluate change over time. The number of drugs and charges tended to increase both for those who did and did not receive PCM services.
Effects of PCM on Resource Utilization
We used several different models to examine the effect of PCM services on inpatient, outpatient, medical service, and emergency department utilization and charges. All models included 18 months of information for utilization (number of claims) or charges (dollars). Independent/control variables included age (continuous), gender, pharmacy intensity (high versus all others or high, moderate, low, none), PCM services (yes/no), a time indicator (1-18 months), and a time by PCM interaction. We used GEE cumulative logistic models for repeated measures with inpatient and emergency department utilization (number of claims ranged from 0 to 5) as the dependent variables. For outpatient and medical service utilization and all charge models, we used GEE normal regression methods for repeated measures. The dependent variable for medical service and outpatient utilization was number of claims (0-11 and 0-67, respectively). Log dollars was the dependent variable for all charge models.
When compared with patients who were eligible but did not receive PCM services, those who received PCM services demonstrated no significant longitudinal differences at the 0.05 level in emergency department, inpatient, outpatient, or medical service utilization or charges ( Table 6 ). The time by PCM P-value for medical service analysis was .086 (Table 6 ) when PCM claims were included and 0.157 excluding PCM claims (not shown).
To evaluate whether there was a dose-response relationship between the intensity with which the service was adopted and effects on health care utilization, we examined the change in emergency department use, inpatient hospitalization, outpatient facility use, and medical/HCFA-1500 claims and charges using the same models as described earlier, testing for an intensity by time interaction. No significant intensity by time interaction was observed in any of the models at the 0.05 level (Table 6) .
Because PCM claims were included in the medical/HCFA-1500 claims file we continued our investigation of the effect of PCM on HCFA-1500 charges. We tested for effects in subgroups of patients. Patients were grouped according to characteristics known to influence receipt of PCM (age, gender, and number of medications). We totaled charges for 6 months before the index date and 12 months after the index date and adjusted the two totals for number of months. We then tested to see if, in any subgroup of patients, those who received PCM differed from those who did not receive PCM in their rate of change in HCFA-1500 charges. We again used GEE repeated-measures "normal" regression methods with log charges as the dependent variable at the two time points. We controlled for age and gender and tested for a significant time by PCM interaction to evaluate change over time. None of the 18 different subgroups had a statistically significant difference between those who received PCM and those who did not in patterns of monthly HCFA-1500 charges over time.
Discussion
The Iowa Medicaid PCM program was developed based on evidence demonstrating that collaboration between pharmacists and physicians improves medication safety. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Throughout the 2-year evaluation period, 1,440 billed services were provided by 114 pharmacies to 690 of 3,037 eligible patients. Physicians accepted 49.2% of pharmacist recommendations, and patients who received PCM services experienced significant improvements in medication use. The most common recommendation was to start a medication, and the most common reason was an untreated or undertreated condition. Discontinuation, changes in drug dose, and switches to alternate drugs also were common recommendations. Improvement in medication use was consistent across different medication problems. This is comparable with results found in a study by Hanlon et al. 3 who found that the percentage of medication problem ratings decreased during the study for 7 of 10 MAI categories in their intervention group. Also of interest is that the problem ratings increased for 5 of the 10 medication problems in the control group of that study. Our mean baseline MAI rating of 9.4 was somewhat lower than those in other studies of pharmacist interventions for high-risk patients for whom mean MAI scores have ranged from about 10 to 15. 3, [30] [31] [32] The Iowa Medicaid PCM program intervention, which resulted in a mean change in MAI score of 1.1 points, appears to be less potent than institutional interdisciplinary team care. The typical change in MAI scores in prior studies has been approximately 4 or 5 points. Previous studies have used the MAI to evaluate interdisciplinary team interventions in institutional settings involving a small number of care providers. In contrast, we used the MAI to study pharmacist interventions in the context of busy dispensing pharmacies. The rate of physician acceptance of pharmacist recommendations (49%) was lower in this study than in hospital-or clinic-based collaborative practice settings, where acceptance rates have ranged from 83% to 95%. [33] [34] [35] [36] Though smaller, our mean change in MAI score following PCM is probably clinically relevant. Schmader et al. 30 found that changes in total MAI scores of 2.0-2.5 points were correlated with emergency department and hospital use and that a change of 1.7 points for cardiac medications was associated with improved blood pressure control. This is the first study to examine the effect of a community pharmacy-physician collaborative intervention on the use of highrisk medications. Provision of PCM services was associated with a decrease in use of high-risk medications among older adults (aged 65 and over) from 43.4% to 32.6%, representing a clinically substantial and statistically significant 24.9% improvement. This was in contrast to PCM-eligible patients who did not receive PCM, among whom the percentage of older adults taking high-risk medications did not change.
Older adults who received PCM services had a higher prevalence of high-risk medication use than did those who did not receive the service. When groups differ at baseline in mean values of the variable of interest, a concern arises that the two groups may have had intrinsic differences in rate of change. This bias is termed selection-maturation interaction. 37 As recommended by Cook and Campbell, 37 to rule out exogenous differing change rates as an explanation for between-group differences, we plotted monthly data from 3 months before through 9 months after initial PCM eligibility (Figure 1) . The plotted lines did not differ in slope until almost 6 months after PCM eligibility. This postintervention change in slope following parallel baseline rates supports an intervention effect and argues against selection-maturation interaction as an alternative explanation.
Health care utilization patterns for patients who received PCM services were similar to those of patients who did not receive PCM services. Health care utilization was a secondary endpoint in this study, and we anticipated that this study would have insufficient power to detect small improvements in these measures, even though these can translate into substantial health and economic benefits. In addition, this was necessarily an evaluation of shortterm effects of PCM. Health status and health care utilization benefits likely require a longer time to be realized. In contrast with other studies, 8, 38 we found no evidence that physician visits increased. We suspect that this can be attributed to the design of the program in which the pharmacist implements the action plan agreed upon after fax communication with the physician without requiring the patient to make a physician office visit.
Despite these positive findings, the PCM program clearly experienced start-up challenges similar to those documented in other studies of community pharmacies. Of 3,037 eligible patients, only 690 patients received full PCM services (22.7%). The main challenges to establishing PCM services were related to patient access, pharmacist issues, physician awareness, and changing the existing systems of care. 22, 39 The effort to start up this new service rested largely with the pharmacist. When a pharmacy received its list of eligible patients, a pharmacist contacted the patients, scheduled appointments, met with them, obtained additional information from their physicians if necessary, completed assessments, and forwarded written recommendations to physicians. Unlike the typical physician's office with staff to perform these types of activities, pharmacies lack such staff. Because of the time needed to complete all of these steps, several months may be required to finalize an action plan for a patient. Additional staff may be needed. In the face of uncertainty about the longevity of the PCM program and the effects of staffing changes on pharmacy finances, managers would be understandably reluctant to make such changes during the initial year of the program.
Physician-pharmacist communication obstacles were evident. Our study of high-risk patients taking multiple medications documented a significant public health problem in a vulnerable population. These patients' health status was far below the national average. They had an extremely high rate of medication problems. In adults aged 65 and older who received PCM services, 43.4% had been taking at least one medication considered to have a poor risk-benefit balance and to be inappropriate for use among older adults. This rate is higher than published rates for community (22%-28%), general Medicaid (27%), and Medicaid nursing home (33%-40%) samples. 40 That these risk indicators identify people who suffer health consequences of inappropriate medication use is supported by the 26% prevalence of adverse drug reactions in the previous year. This rate is alarming and is nearly three times the rate observed in a different population of elderly Iowans not on Medicaid. 2 
Limitations
The program was implemented as a state plan amendment and the Iowa Department of Human Services determined that a randomized trial would not be allowed. The study design was therefore a nonrandomized comparison group design, with the comparison groups consisting of PCM-eligible patients who received the service and PCM-eligible patients who did not receive the service. Those who received PCM were taking more medications and had more medication safety problems at baseline, suggesting that pharmacists tended to select patients with the greatest risk. Supporting the conclusion that improvement in medication safety was attributable to PCM were the findings of dose-response (pharmacy intensity) analyses. Future studies should strive to perform randomized controlled designs, but this is often difficult or impossible when a service such as the Iowa PCM program is implemented for an entire population.
One individual conducted all chart-based MAI reviews. This should not be a serious limitation since individual items in the MAI have demonstrated excellent interrater reliability in previous work (kappa = 0.83 for physician-internist agreement; kappa = 0.64 for two pharmacists) 26 and high interrater reliability has also been obtained for the MAI scores (intraclass correlation coefficient = 0.74). 27 Intrarater reliability of individual items was also high (kappa = 0.92).
Conclusion
PCM services were delivered to Iowa Medicaid patients at high risk of adverse medication experiences. Indeed, 26% of these patients reported experiencing adverse drug reactions in the year before the program, 2.6 times the rate in the general population of older Iowans, using the same survey instrument.
In this report we have described the initial start-up experience with the Iowa Medicaid PCM program that was designed for these high-risk patients. A large number of patients received PCM services and medication safety improved for these patients. Because of the complexity of the program, the complexity of the patient population, and physicians' general unfamiliarity with the PCM concept, the large number of patients who received care must be considered a success.
Developing and sustaining PCM services in community pharmacy is clearly challenging. Implemented as a state plan amendment, the Iowa Medicaid PCM program continues to be available to Iowa's most vulnerable Medicaid patients. The beneficial effects observed among the patients who received these services in the start-up year support efforts to expand this program by enrolling more pharmacy providers, informing patients of their eligibility, raising physician awareness, and developing "best practices" models of community-based physician-pharmacist collaborative PCM.
Lives Interrupted
In 1942 almost 120,000 Japanese Americans were removed from the West Coast. Sent first to hastily established assembly centers in racetracks and fairgrounds, they were eventually moved to 10 relocation camps in hostile and inhospitable locations in the interior. Pharmacy students and pharmacists were among those dispossessed. Students were removed from the University of Washington, Oregon State, University of California-San Francisco, and the University of Southern California. Pharmacy owners were forced to dispose of their businesses within a few short weeks.
A November 1942 survey noted that almost 100 pharmacists were working in the camp hospitals and satellite clinics. A photo of the hospital pharmacy at the Jerome Relocation Camp, Denson, Arkansas, shows pharmacist Yaeko Mayedo labeling a prescription.
Some of the relocation camps remained in operation until late 1945. 
